Alzheimer’s disease (AD) is of growing concern worldwide as the demographic changes to a more aged population. Amyloid-β (Aβ deposition is thought to be a key target for treating AD. However, Aβ antibodies have had mixed results, and there is concern over their safety. Studies have shown that the sigma-2 receptor (σ-2R)/TMEM97 is a binding site for Aβ oligomers. Therefore, targeting the receptor may be beneficial in displacing Aβ oligomers from the brain. CT1812 is a σ-2R/TMEM97 antagonist that is effective in preclinical studies of AD and has been entered into clinical trials.
Objective:
The objective of this study was to systematically review the safety and efficacy of CT1812 for the treatment of AD.
Methods:
Between June and August 2023, we searched the primary literature (PubMed, Scopus, Google Scholar, etc.) and clinical trials databases (http://www.clinicaltrails.gov). The extracted data is evaluated within this manuscript.
Results:
CT1812 is relatively safe, with only mild adverse events reported at doses up to 840 mg. CT1812 can displace Aβ in the clinical studies, in line with the preclinical data. Studies have investigated brain connectivity and function in response to CT1812. However, the cognitive data is still lacking, with only one study including cognitive data as a secondary outcome.
Conclusions:
CT1812 safely works to displace Aβ however, whether this is enough to prevent/slow the cognitive decline seen in AD remains to be seen. Longer clinical trials are needed to assess the efficacy of CT1812; several trials of this nature are currently ongoing.
Gómez-IslaT, HollisterR, WestH, MuiS, GrowdonJH, PetersenRC, ParisiJE, HymanBT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol41, 17–24.
2.
FialaJC, FeinbergM, PetersA, BarbasH (2007) Mitochondrial degeneration in dystrophic neurites of senile plaques may lead to extracellular deposition of fine filaments. Brain Struct Funct212, 195–207.
3.
HolmesC, CunninghamC, ZotovaE, WoolfordJ, DeanC, KerrS, CullifordD, PerryVH (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology73, 768–774.
4.
KimDW, TuKJ, WeiA, LauAJ, Gonzalez-GilA, CaoT, BraunsteinK, LingJP, TroncosoJC, WongPC, BlackshawS, SchnaarRL, LiT (2022) Amyloid-beta and tau pathologies act synergistically to induce novel disease stage-specific microglia subtypes. Mol Neurodegener17, 83.
HeftiF, GoureWF, JerecicJ, IversonKS, WalickePA, KrafftGA (2013) The case for soluble Aβ oligomers as a drug target in Alzheimer’s disease. Trends Pharmacol Sci34, 261–266.
7.
Budd HaeberleinS, AisenPS, BarkhofF, ChalkiasS, ChenT, CohenS, DentG, HanssonO, HarrisonK, von HehnC, IwatsuboT, MallinckrodtC, MummeryCJ, MuralidharanKK, NestorovI, NisenbaumL, RajagovindanR, SkordosL, TianY, van DyckCH, VellasB, WuS, ZhuY, SandrockA (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis9, 197–210.
8.
AvgerinosKI, FerrucciL, KapogiannisD (2021) Effects of monoclonal antibodies against amyloid-βon clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease. Ageing Res Rev68, 101339.
9.
VazM, SilvaV, MonteiroC, SilvestreS (2022) Role of aducanumab in the treatment of Alzheimer’s disease: Challenges and opportunities. Clin Interv Aging17, 797–810.
10.
RahmanA, HossenMA, ChowdhuryMFI, BariS, TamannaN, SultanaSS, HaqueSN, Al MasudA, Saif-Ur-RahmanKM (2023) Aducanumab for the treatment of Alzheimer’s disease: A systematic review. Psychogeriatrics23, 512–522.
11.
MintunMA, LoAC, Duggan EvansC, WesselsAM, ArdayfioPA, AndersenSW, ShcherbininS, SparksJ, SimsJR, BrysM, ApostolovaLG, SallowaySP, SkovronskyDM (2021) Donanemab in early Alzheimer’s disease. N Engl J Med384, 1691–1704.
12.
DoodyRS, ThomasRG, FarlowM, IwatsuboT, VellasB, JoffeS, KieburtzK, RamanR, SunX, AisenPS, SiemersE, Liu-SeifertH, MohsR (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med370, 311–321.
13.
SallowayS, SperlingR, FoxNC, BlennowK, KlunkW, RaskindM, SabbaghM, HonigLS, PorsteinssonAP, FerrisS, ReichertM, KetterN, NejadnikB, GuenzlerV, MiloslavskyM, WangD, LuY, LullJ, TudorIC, LiuE, GrundmanM, YuenE, BlackR, BrashearHR (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med370, 322–333.
14.
OstrowitzkiS, BittnerT, SinkKM, MackeyH, RabeC, HonigLS, CassettaE, WoodwardM, BoadaM, van DyckCH, GrimmerT, SelkoeDJ, SchneiderA, BlondeauK, HuN, QuartinoA, ClaytonD, DoltonM, DangY, OstaszewskiB, Sanabria-BohórquezSM, RabbiaM, TothB, EichenlaubU, SmithJ, HonigbergLA, DoodyRS (2022) Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: Two phase 3 randomized placebo-controlled trials. JAMA Neurol79, 1113–1121.
15.
van DyckCH, SwansonCJ, AisenP, BatemanRJ, ChenC, GeeM, KanekiyoM, LiD, ReydermanL, CohenS, FroelichL, KatayamaS, SabbaghM, VellasB, WatsonD, DhaddaS, IrizarryM, KramerLD, IwatsuboT (2022) Lecanemab in early Alzheimer’s disease. N Engl J Med388, 9–21.
16.
TengE, ManserPT, PickthornK, BrunsteinF, BlendstrupM, Sanabria BohorquezS, WildsmithKR, TothB, DoltonM, RamakrishnanV, BobbalaA, SikkesSAM, WardM, FujiRN, KerchnerGA (2022) Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: A randomized clinical trial. JAMA Neurol79, 758–767.
17.
FlorianH, WangD, ArnoldSE, BoadaM, GuoQ, JinZ, ZhengH, FissehaN, KalluriHV, Rendenbach-MuellerB, BudurK, GoldM (2023) Tilavonemab in early Alzheimer’s disease: Results from a phase 2, randomized, double-blind study. Brain146, 2275–2284.
18.
HayashiT, SuTP (2007) Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell131, 596–610.
19.
MalarDS, ThitilertdechaP, RuckvongacheepKS, BrimsonS, TencomnaoT, BrimsonJM (2023) Targeting Sigma receptors for the treatment of neurodegenerative and neurodevelopmental disorders. CNS Drugs37, 399–440.
20.
BrimsonJM, BrimsonS, ChomchoeiC, TencomnaoT (2020) Using Sigma-ligands as part of a multi-receptor approach to target diseases of the brain. Expert Opin Ther Targets24, 1009–1028.
21.
PrasanthMI, MalarD, TencomnaoT, BrimsonJ (2021) The emerging role of the sigma-1 receptor in autophagy: Hand-in-hand targets for the treatment of Alzheimer’s disease. Expert Opin Ther Targets25, 435–449.
AlonA, SchmidtHR, WoodMD, SahnJJ, MartinSF, KruseAC (2017) Identification of the gene that codes for the σ(2) receptor. Proc Natl Acad Sci U S A114, 7160–7165.
24.
SahnJJ, MejiaGL, RayPR, MartinSF, PriceTJ (2017) Sigma 2 receptor/Tmem97 agonists produce long lasting antineuropathic pain effects in mice. ACS Chem Neurosci8, 1801–1811.
25.
IntagliataS, SharmaA, KingTI, MesangeauC, SeminerioM, ChinFT, WilsonLL, MatsumotoRR, McLaughlinJP, AveryBA, McCurdyCR (2020) Discovery of a highly selective sigma-2 receptor ligand, 1-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with drug-like properties and antinociceptive effects In Vivo. AAPS J22, 94.
26.
Vázquez-RosaE, WatsonMR, SahnJJ, HodgesTR, SchroederRE, Cintrón-PérezCJ, ShinMK, YinTC, EmeryJL, MartinSF, LieblDJ, PieperAA (2019) Neuroprotective efficacy of a sigma 2 receptor/TMEM97 modulator (DKR-1677) after traumatic brain injury. ACS Chem Neurosci10, 1595–1602.
27.
XuJ, ZengC, ChuW, PanF, RothfussJM, ZhangF, TuZ, ZhouD, ZengD, VangveravongS, JohnstonF, SpitzerD, ChangKC, HotchkissRS, HawkinsWG, WheelerKT, MachRH (2011) Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun2, 380.
28.
ZengC, VangveravongS, McDunnJE, HawkinsWG, MachRH (2013) Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer. Br J Cancer109, 2368–2377.
29.
ChuUB, MavlyutovTA, ChuML, YangH, SchulmanA, MesangeauC, McCurdyCR, GuoLW, RuohoAE (2015) The Sigma-2 receptor and progesterone receptor membrane component 1 are different binding sites derived from independent genes. EBioMedicine2, 1806–1813.
AhmedISA, ChamberlainC, CravenRJ (2012) S2RPgrmc1: The cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling. Expert Opin Drug Metab Toxicol8, 361–370.
32.
HiranitaT (2016) Identification of the sigma-2 receptor: Distinct from the progesterone receptor membrane component 1 (PGRMC1). J Alcohol Drug Depend4. doi: 10.4172/2329-6488.1000e130.
33.
PatiML, GrozaD, RigantiC, KopeckaJ, NisoM, BerardiF, HagerS, HeffeterP, HiraiM, TsugawaH, KabeY, SuematsuM, AbateC (2017) Sigma-2 receptor and progesterone receptor membrane component 1 (PGRMC1) are two different proteins: Proofs by fluorescent labeling and binding of sigma-2 receptor ligands to PGRMC1. Pharmacol Res117, 67–74.
34.
RiadA, ZengC, WengCC, WintersH, XuK, MakvandiM, MetzT, CarlinS, MachRH (2018) Sigma-2 receptor/TMEM97 and PGRMC-1 increase the rate of internalization of LDL by LDL receptor through the formation of a ternary complex. Sci Rep8, 16845.
35.
RiadA, Lengyel-ZhandZ, ZengC, WengCC, LeeVM, TrojanowskiJQ, MachRH (2020) The sigma-2 receptor/TMEM97, PGRMC1, and LDL receptor complex are responsible for the cellular uptake of Aβ 42 and its protein aggregates. Mol Neurobiol57, 3803–3813.
36.
YiB, SahnJJ, ArdestaniPM, EvansAK, ScottLL, ChanJZ, IyerS, CrispA, ZunigaG, PierceJT, MartinSF, ShamlooM (2017) Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer’s disease. J Neurochem140, 561–575.
37.
KargboRB (2021) Sigma-1 and sigma-2 receptor modulators as potential therapeutics for Alzheimer’s disease. ACS Med Chem Lett12, 178–179.
38.
YangK, ZengC, WangC, SunM, YinD, SunT (2020) Sigma-2 receptor-A potential target for cancer/Alzheimer’s disease treatment via its regulation of cholesterol homeostasis. Molecules25, 5439.
39.
IzzoNJ, StaniszewskiA, ToL, FaM, TeichAF, SaeedF, WosteinH, WalkoT 3rd, VaswaniA, WardiusM, SyedZ, RavenscroftJ, MozzoniK, SilkyC, RehakC, YurkoR, FinnP, LookG, RishtonG, SaffersteinH, MillerM, JohansonC, StopaE, WindischM, Hutter-PaierB, ShamlooM, ArancioO, LeVineH 3rd, CatalanoSM (2014) Alzheimer’s therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. PLoS One9, e111898.
40.
IzzoNJ, YuedeCM, LaBarberaKM, LimegroverCS, RehakC, YurkoR, WaybrightL, LookG, RishtonG, SaffersteinH (2021) Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer’s disease modification. Alzheimers Dement17, 1365–1382.
41.
RishtonGM, LookGC, NiZJ, ZhangJ, WangY, HuangY, WuX, IzzoNJ, LaBarberaKM, LimegroverCS, RehakC, YurkoR, CatalanoSM (2021) Discovery of investigational drug CT1812, an antagonist of the sigma-2 receptor complex for Alzheimer’s disease. ACS Med Chem Lett12, 1389–1395.
42.
GrundmanM, MorganR, LickliterJD, SchneiderLS, DeKoskyS, IzzoNJ, GuttendorfR, HigginM, PribylJ, MozzoniK (2019) A Phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer’s disease. Alzheimers Dement (N Y)5, 20–26.
43.
BrimsonJM, BrimsonS, PrasanthMI, ThitilertdechaP, MalarDS, TencomnaoT (2021) The effectiveness of Bacopa monnieri (Linn.) Wettst. as a nootropic, neuroprotective, or antidepressant supplement: Analysis of the available clinical data. Sci Rep11, 596.
44.
LaBarberaKM, ShelineYI, IzzoNJ, YuedeCM, WaybrightL, YurkoR, EdwardsHM, GardinerWD, BlennowK, ZetterbergH, Börjesson-HansonA, MorganR, DavisCS, GuttendorfRJ, SchneiderLS, DeKoskyS, LeVineH 3rd, GrundmanM, CaggianoAO, CirritoJR, CatalanoSM, HambyME (2023) A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter. Transl Neurodegener12, 24.
45.
CatalanoS, GrundmanM, SchneiderLS, DeKoskyS, MorganR, HigginM, PribylJ, MozzoniK, IzzoNJ, SaffersteinH, LickliterJ (2016) P4-381: A two-part, double-blind, placebo-controlled, Phase 1 study of the safety and pharmacokinetics of single and multiple ascending doses of CT1812 in healthy volunteers.. Alzheimers Dement12, P1183–P1184.
46.
CognitionTheraputics, Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease,https://ir.cogrx.com/node/8531/pdf, Accessed 11/07/2023.
47.
CatalanoS, GrundmanM, SchneiderLS, DeKoskyS, MorganR, GuttendorfR, HigginM, PribylJ, MozzoniK, IzzoNJ (2017) [P4–567]: A Phase 1 safety trial of the Aβ oligomer receptor antagonist CT1812. Alzheimers Dement13, P1570–P1570.
48.
MonllorP, Cervera-FerriA, LloretMA, EsteveD, LopezB, LeonJL, LloretA (2021) Electroencephalography as a non-invasive biomarker of Alzheimer’s disease: A forgotten candidate to substitute CSF molecules? . Int J Mol Sci22, 10889.
49.
PinedaAM, RamosFM, BettingLE, CampanharoASLO (2020) Quantile graphs for EEG-based diagnosis of Alzheimer’s disease. PLoS One15, e0231169.
50.
MorrisGP, ClarkIA, VisselB (2014) Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer’s disease. Acta Neuropathol Commun2, 135.
51.
MusiekES, Gomez-IslaT, HoltzmanDM (2021) Aducanumab for Alzheimer disease: The amyloid hypothesis moves from bench to bedside. J Clin Invest131, e154889.
52.
DonohueMC, SperlingRA, PetersenR, SunCK, WeinerMW, AisenPS; Alzheimer’s Disease Neuroimaging Initiative (2017) Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA317, 2305–2316.
SchneiderL (2020) A resurrection of aducanumab for Alzheimer’s disease. Lancet Neurol19, 111–112.
55.
SöderbergL, JohannessonM, NygrenP, LaudonH, ErikssonF, OsswaldG, MöllerC, LannfeltL (2023) Lecanemab, Aducanumab, and Gantenerumab — binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer’s disease. Neurotherapeutics20, 195–206.
56.
MaWH, ChenAF, XieXY, HuangYS (2021) Sigma ligands as potent inhibitors of Aβ and Aβ Os in neurons and promising therapeutic agents of Alzheimer’s disease. Neuropharmacology190, 108342.
57.
ChenAF, MaWH, XieXY, HuangYS (2021) Sigma-2 receptor as a potential drug target. Curr Med Chem28, 4172–4189.
